Patent ID: 8992924
Filing Date: 2015-03-31
Classification: A61K,A61P,C07K,G01N,Y10S

Abstract:
1. A method of treating a human subject having a disease mediated by αvβ6, comprising administering to the subject a humanized antibody or an antigen binding fragment thereof that specifically binds to αvβ6, thereby alleviating or postponing the onset of the disease, wherein the antibody or the antigen binding fragment thereof comprises: (a) a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:144, SEQ ID NO:145, or SEQ ID NO:146 and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, or SEQ ID NO:143; (b) a heavy chain variable domain comprising a variant of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the variant of SEQ ID NO: 1 comprises one or both of Q3M and N73S amino acid substitutions in SEQ ID NO:1; (c) a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:1 and a light chain variable domain comprising a variant of the amino acid sequence set forth in SEQ ID NO:2, wherein the variant of SEQ ID NO:2 comprises one or more amino acid substitutions selected from the group consisting of L48W, I59V, A61V and Y88F in SEQ ID NO:2; or (d) a heavy chain variable domain comprising a variant of the amino acid sequence set forth in SEQ ID NO:1 and a light chain variable domain comprising a variant of the amino acid sequence set forth in SEQ ID NO:2, wherein the variant of SEQ ID NO:1 comprises one or both of Q3M and N73S amino acid substitutions in SEQ ID NO:1 and the variant of SEQ ID NO:2 comprises one or more of the amino acid substitutions selected from the group consisting of L48W, I59V, A61V and Y88F in SEQ ID NO:2, wherein the disease mediated by αvβ6 is fibrosis, Alport's Syndrome, acute lung injury, or acute kidney injury.